Althaus C, Dagres E, Reinhard T, Christians U, Sundmacher R
Universitäts-Augenklinik, Heinrich-Heine-Universität, Düsseldorf, Germany.
Ger J Ophthalmol. 1996 Jul;5(4):189-94.
Penetration of cyclosporin A (CSA) into the anterior chamber through the intact cornea after topical application is difficult due to its hydrophobic structure. Following systemic application the anterior-chamber levels of CSA are reported to be higher. CSA metabolites are more hydrophilic than CSA. Only high-performance liquid chromatography-electrospray mass spectrometry allows exact quantification of the CSA level and the identification of all CSA metabolites. We studied the anterior-chamber levels of CSA and different CSA metabolites after topical and systemic application. CSA and CSA-metabolite anterior-chamber levels were measured in 49 patients after topical application of CSA 2% eye drops preceding routine cataract surgery with 2 different application schemes and in 7 patients receiving systemic CSA after high-risk penetrating keratoplasty. After topical application the average CSA level measured in the anterior chamber was 81 ng/ml. The CSA-metabolite levels were much higher, reaching an average of 378 ng/ml. After systemic therapy the anterior-chamber levels of CSA and of the metabolites were much more balanced at 256 and 317 ng/ml, respectively. CSA penetrates into the anterior chamber after topical eye-drop application, but these levels are much lower than those measured after systemic CSA therapy. After topical application the CSA metabolites might play an important role; they are found in the anterior chamber in much higher concentrations than is CSA, and the metabolite pattern differs from that seen after systemic therapy. The relevance of these findings to the immunosuppressive activity of the CSA metabolites, however, remains unclear.
由于环孢素A(CSA)的疏水性结构,局部应用后其通过完整角膜进入前房较为困难。据报道,全身应用后CSA在前房的水平较高。CSA代谢产物比CSA更具亲水性。只有高效液相色谱 - 电喷雾质谱法能够准确量化CSA水平并鉴定所有CSA代谢产物。我们研究了局部和全身应用后CSA及不同CSA代谢产物在前房的水平。在49例患者中,于常规白内障手术前采用2种不同的应用方案局部应用2%的CSA滴眼液后,以及在7例高危穿透性角膜移植术后接受全身CSA治疗的患者中,测量了CSA和CSA代谢产物在前房的水平。局部应用后,前房中测量的平均CSA水平为81 ng/ml。CSA代谢产物水平则高得多,平均达到378 ng/ml。全身治疗后,CSA和代谢产物在前房的水平更为平衡,分别为256 ng/ml和317 ng/ml。局部应用滴眼液后CSA可进入前房,但这些水平远低于全身应用CSA治疗后测得的水平。局部应用后CSA代谢产物可能起重要作用;它们在前房中的浓度比CSA高得多,且代谢产物模式与全身治疗后所见不同。然而,这些发现与CSA代谢产物免疫抑制活性的相关性仍不清楚。